Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516639) titled 'First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics' on April 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd.
Condition:
Healthy Subjects (HS)
SLE (Systemic Lupus)
Intervention:
Drug: ISH0613 for injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 1, 2026
Target Sample Size: 26
Countries of Recruitment:
China
To know more, visit h...